At 10:30 IST, the barometer index, the S&P BSE Sensex, rose 20.55 points or 0.03% to 80,460.37. The Nifty 50 index added 18 points or 0.07% to 24,559.15.
The broader market outperformed the frontline indices. The S&P BSE Mid-Cap index added 0.52% and the S&P BSE Small-Cap index gained 1.19%.
The market breadth was strong. On the BSE, 2,643 shares rose and 1,031 shares fell. A total of 160 shares were unchanged.
Economy:
Indias forex reserves declined $4.8 billion to $670.119 billion for the week ended August 9, according to the latest RBI data.
In the previous reporting week, the countrys foreign exchange reserves had increased $7.533 billion to an all-time high of $674.919 billion.
More From This Section
For the week ended August 9, foreign currency assets, a major component of the reserves, decreased by $4.079 billion to $587.96 billion.
Gold reserves declined by $860 million to $59.239 billion during the week. The special drawing rights (SDRs) were up by $121 million to $18.282 billion.
Indias reserve position with the IMF increased by $18 million to $4.638 billion in the reporting week, the central bank data showed.
Buzzing Index:
The Nifty Media index added 2.17% to 2,104.35. The index advanced 4.31% in the two trading sessions.
V18 Broadcast (up 4.21%), Network 18 Media & Investments (up 3.05%), Saregama India (up 2.64%), PVR Inox (up 2.6%), Hathway Cable & Datacom (up 1.78%), Tips Industries (up 1.75%), Dish TV India (up 1.24%), Zee Entertainment Enterprises (up 1.15%), Nazara Technologies (up 0.55%) and Sun TV Network (up 0.21%) edged higher.
Stocks in Spotlight:
Caplin Point Laboratories soared 8.40% after the Brazilian Health Regulatory Agency (ANVISA) conducted inspection at its Chennai facility between 12 and 16 August 2024 and concluded with zero observations.
Techno Electric & Engineering Company (Techno Electric) hits upper circuit of 5% after the company partnered with IndiGrid to develop two IndiGrids Greenfield interstate transmission Systems (ISTS) projects.
Glenmark Pharmaceuticals added 2.89% after the companys subsidiary Glenmark Therapeutics Inc., USA, announced the launch of OTC product Olopatadine Hydrochloride Ophthalmic Solution.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content